Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


St. Jude To Acquire CardioMEMS As FDA Approves Heart Failure Monitor

This article was originally published in The Gray Sheet

Executive Summary

FDA approved the CardioMEMS HF wireless heart-failure monitor, and St. Jude has exercised its option to buy the technology and its manufacturer. The approval is based on the results of the CHAMPION pivotal trial, which showed that patients monitored with the remote, implantable system needed fewer hospitalizations.

You may also be interested in...

CardioMEMS Heart Failure Monitor Shows Mortality, Hospitalization Benefit

A retrospective analysis presented at the American College of Cardiology meeting in San Diego shows that pulmonary artery pressure monitoring with St. Jude’s CardioMEMS reduced hospitalization and mortality in patients with heart failure and reduced ejection fraction.

Medicare Add-On Payments Granted For Cardiac, Neuro Devices

CMS agreed to grant new tech add-on payments to St. Jude’s CardioMEMS implantable heart failure monitoring system and Abbott’s MitraClip mitral valve repair system, but it took some convincing. The agency also granted an add-on for NeuroPace’s RNS responsive neurostimulator system to treat seizures.

PMA Data: High Approval Volume, Reduced Supplement Review Time For May

FDA achieved highs in the volume of original PMAs and supplements approved in May, and lows in PMA supplement review times for approvals that month, according to analysis by “The Gray Sheet” of the agency’s most recent official monthly PMA listing. Exclusive graphical elements included.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts